/ /

  • linkedin
  • Increase Font
  • Sharebar

    Epi-on CXL: Safe, effective option for treating thin corneas

    Procedure can also be repeated safely, if necessary

     

    By 1-year postoperatively, 153 eyes had completed their follow-up. The average improvement in the UCVA was 2.26 lines and the average improvement in the BCVA vision was 0.79 line. The average Kmax improvement from baseline value was 1.18 D of flattening, and the average decreased in the refractive astigmatism was 0.38 D.

    Sixty-two eyes completed the 2-year follow-up, when the average improvement in the UCVA was 2.65 lines and in the average improvement in the BCVA vision was 1.18 lines. The average Kmax improvement from the baseline value was 1.23 D of flattening and the average decreased in the refractive astigmatism was 0.81 D.

    A case study demonstrated the progressive improvement seen after the Epi-on CXL procedure.  In this case of a 68-year-old man, his preoperative Kmax value was 50.6 D, 18 months after surgery the KMax was 45.9 D, and at 3 years the Kmax was 44.9 D.

    CXL is effective for stopping progression of keratoconus, post-LASIK ectasia, and pellucid marginal degeneration, Dr. Trattler reported. In addition, CXL can help improve the corneal shape, UCVA, BCVA and quality of vision. 

    If progression occurs after either the Epi-off or Epi-on CXL procedures, the treatment can be repeated safely, he said.

    “Our clinical study showed that the Epi-on CXL procedure with pulsed UV light for treating patients with thin corneas appears to be as effective as the Epi-off procedure,” Dr. Trattler concluded.

     

    William Trattler, MD

    E: [email protected]

    Dr. Trattler has a financial interest in this technology. He was joined in this data analysis by Roy Rubinfeld, MD, MA, who has a financial interest in this technology.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results